The advent of incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their combinations, as pharmacological treatments for obesity and type 2 diabetes, has sparked intense debate about their role relative to traditional lifestyle interventions such as exercise and dietary modification. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.